TTP488 has been reported to serve as an antagonist of the RAGE-RAGE ligand interaction through various clinical trials and is applied for AD therapy (32); however, studies on TTP488 are relatively lacking, and the mechanisms whereby TTP488 ameliorates AD injury have not yet been fully clarified. This evidence concerns the gene AGER and Alzheimer disease.